TrippBio

TrippBio


About this raise: TrippBio, with a post-money valuation of $7.1 million, is raising funds on NetCapital. The company is developing a new therapeutic application of an FDA-approved drug for the treatment and prevention of the SARS-CoV-2 virus. The company believes that the drug TD213 is capable of preventing the host cell from assembling the virus that causes COVID-19. Billy Meadow and Richard Still founded TrippBio in May 2020. The current round of crowdfunding has a minimum raise of $10,000 and a maximum raise of $1,070,000, and the funds will be used for initial clinical trial, development and manufacturing of TD213, marketing and advertising, professional services, and ramp-up clinical trial. TrippBio is well-positioned to help the world combat COVID-19 and other infectious diseases.

Expand

Investment Overview

Invested this round: $185,796

Deal Terms

Total Commitments ($USD)

Platform
Netcapital
Start Date
09/16/2020
Close Date
01/29/2021
Min. Goal
$10,000
Max. Goal
$1,070,000
Min. Investment

$100

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Price Per Share

$4.00

Pre-Money Valuation

$5,255,840

Company & Team

Company

Year Founded
2020
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Location
Jacksonville, Florida
Business Type
Growth
Company Website
Visit Website

Team

Employees
18

Financials

 Revenue
$0
 Cash on Hand
$0

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$0

$0

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$0

$0

Accounts Receivable

$0

$0

Total Assets

$0

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
02/11/2025 StartEngine $24,820,583 $6,633 Equity - Common Active RegCF
01/29/2021 Netcapital $5,255,840 $185,796 Equity - Common Funded RegCF / RegD 506(c)
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Add to portfolio
TrippBio on NetCapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $5,255,840
Price per Share: $4.00

Follow company

Follow TrippBio on NetCapital

Buy TrippBio's Deal Report

Warning: according to the close date for this deal, TrippBio may no longer be accepting investments.

TrippBio Deal Report

Get Kingscrowd's comprehensive report on TrippBio including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether TrippBio is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the TrippBio deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge